Bolus Administration of Intravenous Lidocaine at the Time of Abdominal Hysterectomy

Aswan University Hospital

Status: Completed

Conditions: Abdominal Hysterectomy

Treatments: Drug: Placebo; Drug: lidocaine

Study type: Interventional

Funder types: Other

Identifiers

NCT03748108

aswu/275/18

Details and patient eligibility

About

The objective of the study to evaluate whether a bolus administration of intravenous lidocaine decreases postoperative pain and represents an opioid-minimizing strategy after abdominal hysterectomy compared with placebo.

Full description

Total abdominal hysterectomy (TAH) is the most common gynecological operation worldwide. Some studies noticed about abused of opioids in postoperative care, led to a more adverse effect of opioids, slow recovery, prolong the length of hospitalized stay and consequently increase the unnecessary cost of treatment.

Guidelines have considered using preoperative analgesics for reducing post-operative opioids consumption, including lidocaine infusion. With its anti-inflammatory, anti-hyperalgesia and analgesic properties, intravenous perioperative lidocaine infusion (IVLI) has been used for optimal postoperative care in different surgeries and in various procedures involving hysterectomy.

Therefore, the aim of this study is to assess the efficacy of bolus administration of intravenous lidocaine at the time of abdominal hysterectomy to decrease postoperative pain and reducing morphine requirements, after TAH.

Enrollment: 120 patients

Sex: Female

Ages: 35 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women ranging age between 35-60 years a who undergoing elective total abdominal hysterectomy

Exclusion criteria

• Participants had known sensitivity to lidocaine
• Participants had difficulty in intubation
• Participants were on chronic pain medication or already on long-term opioids
• Participants smokers
• Participants with disabilities who were unable to communicate pain levels
• refuse to consent

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

120 participants in 2 patient groups, including a placebo group

lidocaine

Experimental group

Description:

A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.

Treatment:

Drug: lidocaine

Placebo

Placebo Comparator group

Description:

A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.

Treatment:

Drug: Placebo